Skip to Content
Merck
  • Kidney function in the very elderly with hypertension: data from the hypertension in the very elderly (HYVET) trial.

Kidney function in the very elderly with hypertension: data from the hypertension in the very elderly (HYVET) trial.

Age and ageing (2012-08-23)
Ruth Peters, Nigel Beckett, Ruth Poulter, Lisa Burch, Krzysztof Narkiewicz, Robert Fagard, Dorothea Nitsch, Nan Wang, Mengying Li, Astrid Fletcher, Christopher Bulpitt
ABSTRACT

numerous reports have linked impaired kidney function to a higher risk of cardiovascular events and mortality. There are relatively few data relating to kidney function in the very elderly. the Hypertension in the Very Elderly Trial (HYVET) was a randomised placebo-controlled trial of indapamide slow release 1.5mg ± perindopril 2-4 mg in those aged ≥80 years with sitting systolic blood pressures of ≥160 mmHg and diastolic pressures of <110 mmHg. Kidney function was a secondary outcome. HYVET recruited 3,845 participants. The mean baseline estimated glomerular filtration rate (eGFR) was 61.7 ml/min/1.73 m(2). When categories of the eGFR were examined, there was a possible U-shaped relationship between eGFR, total mortality, cardiovascular mortality and events. The nadir of the U was the eGFR category ≥60 and <75 ml/min/1.73 m(2). Using this as a comparator, the U shape was clearest for cardiovascular mortality with the eGFR <45 ml/min/1.73 m(2) and ≥75 ml/min/1.73 m(2) showing hazard ratios of 1.88 (95% CI: 1.2-2.96) and 1.36 (0.94-1.98) by comparison. Proteinuria at baseline was also associated with an increased risk of later heart failure events and mortality. although these results should be interpreted with caution, it may be that in very elderly individuals with hypertension both low and high eGFR indicate increased risk.

MATERIALS
Product Number
Brand
Product Description

Supelco
Indapamide, analytical standard, for drug analysis
Sigma-Aldrich
Perindopril erbumine